Arbutus Biopharma Corporation (NASDAQ:ABUS) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, November 1st. Analysts expect Arbutus Biopharma Corporation to post earnings of ($0.37) per share for the quarter.

Shares of Arbutus Biopharma Corporation (NASDAQ ABUS) opened at 5.875 on Wednesday. The stock’s market cap is $323.28 million. Arbutus Biopharma Corporation has a 1-year low of $2.35 and a 1-year high of $8.25. The stock’s 50 day moving average price is $6.22 and its 200 day moving average price is $4.27.

Several analysts have weighed in on ABUS shares. Zacks Investment Research downgraded Arbutus Biopharma Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. Chardan Capital reaffirmed a “buy” rating on shares of Arbutus Biopharma Corporation in a research note on Monday, August 7th. Wedbush reaffirmed an “outperform” rating and set a $9.00 target price on shares of Arbutus Biopharma Corporation in a research note on Wednesday, September 20th. ValuEngine raised Arbutus Biopharma Corporation from a “sell” rating to a “hold” rating in a research note on Thursday, September 21st. Finally, JMP Securities reaffirmed an “outperform” rating and set a $13.00 target price (up previously from $12.00) on shares of Arbutus Biopharma Corporation in a research note on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. Arbutus Biopharma Corporation has an average rating of “Buy” and an average target price of $15.00.

In other news, insider Michael J. Sofia sold 10,000 shares of the business’s stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $8.00, for a total value of $80,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Michael J. Sofia sold 30,000 shares of the business’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $3.70, for a total value of $111,000.00. Following the completion of the sale, the insider now directly owns 1,563,403 shares in the company, valued at approximately $5,784,591.10. The disclosure for this sale can be found here. 10.00% of the stock is owned by insiders.

An institutional investor recently raised its position in Arbutus Biopharma Corporation stock. Vanguard Group Inc. lifted its position in Arbutus Biopharma Corporation (NASDAQ:ABUS) by 2.7% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 77,413 shares of the biopharmaceutical company’s stock after buying an additional 2,035 shares during the period. Vanguard Group Inc. owned approximately 0.14% of Arbutus Biopharma Corporation worth $279,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 67.00% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Arbutus Biopharma Corporation (ABUS) Scheduled to Post Earnings on Wednesday” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/25/arbutus-biopharma-corporation-abus-scheduled-to-post-earnings-on-wednesday.html.

Arbutus Biopharma Corporation Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Earnings History for Arbutus Biopharma Corporation (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.